Traditional dosage: One tablet (150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 300 mg of tenofovir disoproxil fumarate) once daily, with food. For those 12 or older, who weigh at least 35 kg, and are new to antiretroviral therapy; or as a replacment regimen for those virologically suppressed on their current regimen for at least 6 months, who have no previous virologic failures, and no drug resistance to Stribild components.
Drug interactions, precautions, & recommendations: Do not use with other HIV drugs containing emtricitabine or tenofovir disoproxil fumarate (Atripla, Complera, Emtriva, Truvada, Viread), lamivudine, ritonavir (Combivir, Epivir, Epivir-HBV, Epzicom, Trizivir), or tenofovir alafenamide (Genvoya, Odefsey, Descovy); the HBV drug Vemlidy; ritonavir or other drugs containing cobicistat (Evotaz, Prezcobix); or Revatio, Hepsera, alfuzosin, rifampin, cisapride, lurasidone, pimozide, St John’s Wort; ergot derivatives (dihydroergotamine, ergotamine, methylergonovine), HMG-CoA Reductase inhibitors (lovastatin, simvastatin), anticonvulsants (carbamazepine, phenobarbital, phenytoin); or with sedative hypnotics. Avoid if taking Quetiapine for schizophrenia or Ledipasvir for hepatitis C treatment. Not FDA approved for hepatitis B treatment. Not recommended if you have a creatinine clearance below 70 ml/minute.
Side effects: buildup of lactic acid in blood; severe liver or kidney problems, which could lead to potentially fatal renal failure; thinning bones; changes in immune system